InSysBio to participate in QSPC 2026

events
Conference
March 12, 2026

InSysBio announces its participation in Quantitative Systems Pharmacology Conference (QSPC) 2026 which is to be held from April 8-10, 2026 in Leiden, the Netherlands. InSysBio team is going to present its QSP modeling services & software to optimize drug development at Booth #3 and posters, namely:

  • "When Good Fits Are Not Enough: Practical Identifiability with LikelihoodProfiler.jl" by Ivan Borisov, Evgeny Metelkin
  • "A QSP model for LNP-mRNA delivery reveals decoupled determinants of mRNA and encoded protein kinetics" by Veronika Musatova1, Anastasiia Ivanova1, Kseniia Kudriavtseva1, Oleg Demin2, Rajat Desikan3

Affiliations: (1) InSysBio CY; (2) InSysBio UK; (3) Clinical Pharmacology Pharmacometric Systems and Tools, Platform Sciences, GSK, UK

  • "Mixed-Integer Optimization for Virtual Population Selection in QSP Models" by Ivan Borisov, Evgeny Metelkin
  • "Mechanistic modeling of cytotoxicity mechanisms of antibodies to the CD20 receptor in relation to B lymphocytes" by Dmitrii Gordeev, Tatiana Karelina, Oleg Demin
  • "Model-Informed Prediction of First-in-Human Starting Dose and Step-Up Regimen for a T-Cell Engager" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov

Moreover, InSysBio will hold a workshop on Heta at Golden Tulip & Tulip Inn Leiden Centre, Leiden, the Netherlands on April 7, 2026, 1 PM – 5 PM. This workshop will introduce an engineering-style approach to QSP modeling using the Heta language and tools. Participants will explore structured and modular model descriptions, improved transparency, and practical workflows that support scalable and reproducible model development.

Register here

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com